



IFW  
\$

Express Mail No.: EV 913 330 447 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Dingivan, Christine A.

Confirmation No.: 7146

Application No.: 10/091,313

Group Art Unit: 1644

Filed: March 4, 2002

Examiner: Skelding, Zachary S.

For: METHODS OF PREVENTING OR  
TREATING INFLAMMATORY OR  
AUTOIMMUNE DISORDERS BY  
ADMINISTERING CD2 BINDING  
MOLECULES IN COMBINATION WITH  
ANTI-ANGIOGENIC AGENTS (as  
amended)

Attorney Docket No.: 10271-063-999

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

05/22/2007 AADOF01 00000010 503013 10091313  
01 FC:1806 100.00 DA

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references A81-A96, B25-B26 and C159-C183 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references A93-A96, B25-B26 and C159-C183 are submitted herewith. Copies of references A81-A92 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed reference is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such reference is available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. §1.97(b), since this information disclosure statement is being filed after the mailing date of a first Office Action on the merits, a fee of \$180 is believed to be due in connection herewith. Please charge the required fee to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: May 17, 2007

Anthony M. Inoogna 35,203  
Anthony M. Inoogna (Reg. No.)

By: Jennifer J. Chheda 46,617  
Jennifer J. Chheda (Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, NY 10017  
(212) 326-3939

Enclosures



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>10271-063-999</b>	APPLICATION NO. <b>10/091,313</b>
	APPLICANT <b>Dingivan</b>	
	FILING DATE <b>March 4, 2002</b>	ART UNIT <b>1644</b>

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A81	2,060,480	11/10/36	Arnold	
	A82	4,980,358	12/25/90	Smith	
	A83	5,587,459	12/24/96	Uckun	
	A84	5,872,223	02/16/99	Uckun	
	A85	5,925,376	07/20/99	Heng	
	A86	6,037,454	03/14/00	Jardieu et al.	
	A87	6,218,410	04/17/01	Uehata et al.	
	A88	6,451,812	09/17/02	End et al.	
	A89	6,582,698	06/24/03	Dedrick et al.	
	A90	2003/0044406	03/06/03	Dingivan	
	A91	2003/0083263	05/01/03	Doronina et al.	
	A92	2004/0127682	07/01/04	Neville et al.	
	A93	60/409,024	09/05/02	Dingivan	
	A94	60/410,385	09/12/02	Dingivan	
	A95	10/091,268	03/04/02	Dingivan	
	A96	10/657,006	09/05/03	Dingivan et al.	


### FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B25	WO 98/07444	02/26/98	Biotransplant, Inc.		
	B26	WO 02/40049	05/23/02	The General Hospital Corporation		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C159	AU et al., 1996, "Peripheral T-cell lymphoma," Curr. Oncol. Rep. 4(5):434-42	
	C160	BERLIN et al., 1992, "Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates," Transplantation 53(4):840-849	
	C161	CROFFORD and WILDER, 1993, "Arthritis and autoimmunity in animals," in: Arthritis and Allied Conditions:	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	



<b>LIST OF REFERENCES SUBMITTED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10271-063-999	10/091,313
	APPLICANT <b>Dingivan</b>	
	FILING DATE	ART UNIT
	March 4, 2002	1644

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		A Textbook of Rheumatology, McCarty et al., eds., Lee & Febiger, Chapter 29	
	C162	DEARDEN et al., 2002, "Alemtuzumab in T-cell malignancies," Med. Oncol. 19 Suppl:S27-32	
	C163	DEARDEN et al., 2001, "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H," Blood 98(6):1721-1726	
	C164	DE LA PARRA, et al., 1991, "Inhibition of T-Cell Activation by Lo-CD2-a, A Rat monoclonal Antibody Against the Human CD2 Glycoprotein," Belgian Journal of Zoology 121(Supp.1):13 Abstract 16	
	C165	DENARDO et al., 1998, "Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts," Clin. Cancer Res. 4(10):2483-2490	
	C166	DENNING et al., 1987, "Monoclonal antibodies to CD2 and lymphocyte function-associated antigen 3 inhibit human thymic epithelial cell-dependent mature thymocyte activation," J. Immunol. 139(8):2573-2578	
	C167	FELDMAN et al., 1998, "Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases," Transplant. Proc. 30(8):4126-7	
	C168	FUJIWARA et al., 2002, "Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma," Acta. Haematol. 107(4):213-219	
	C169	KODAMA et al., 2002, "Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies," Immunol. Lett. 81(2):99-106	
	C170	LIN et al., 1994, "Peripheral T-cell lymphoma in childhood: A report of five cases in Taiwan," Med. And Ped. Oncol. 23:26-35	
	C171	LIN et al., 1996, "Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CD3," Cell. Immunol. 167(2):249-58	
	C172	LINDEN et al., 1999, "Psoriasis: Current Perspectives with an Emphasis on Treatment," Am. J. Med. 107(6):595-605	
	C173	MESTAS et al., 2004, "Of mice and not men: differences between mouse and human immunology," J. Immunol. 172(5):2731-8	
	C174	MOHAMMAD et al., 1999, "A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model," Int. J. Oncol. 15(2):367-372	
	C175	NIZET et al., 1999, "Apoptosis of human naive NK cells mediated by a rat IgG2b anti CD2 mAb through a fratricidal ADCC reaction," Immunol. Lett. 68(2-3):229-35	
	C176	PETERSON et al., 1987, "Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2)," Nature 329(6142):842-846	
	C177	PHILLIPS et al., 2000, "IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction," Cancer Res. 60(24):6977-6984	
	C178	TAKEMORI et al., 1995, "Significance of PUVA therapy for adult T-cell leukemia/lymphoma - PUVA therapy can induce apoptosis in leukemic cells," Hum. Cell. 8(3):121-126	
	C179	VAN NOORT et al., 1998, "Cell biology of autoimmune diseases," Int. Rev. Cytol. 178:127-206	
	C180	WHITE et al., 1989, "Peripheral T cell lymphoma: value of bone marrow trephine immunophenotyping," J. Clin. Pathol. 42:403-408	
	C181	WOYKE et al., 2002, "Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans," Antimicrob. Agents. Chemother. 46(12):3802-3808	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>10271-063-999</b>	APPLICATION NO. <b>10/091,313</b>
	APPLICANT <b>Dingivan</b>	
	FILING DATE <b>March 4, 2002</b>	ART UNIT <b>1644</b>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C182	WOYKE et al., 2001, "In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE," Antimicrob. Agents Chemother. 45(12):3580-3584	
	C183	ZHANG et al., 2003, "Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507," Blood 102(1):284-8	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	